MSAM
TXMD icon

Moloney Securities Asset Management’s TherapeuticsMD TXMD Stock Holding History

Moloney Securities Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-324
Closed -$20K – 435
2020
Q4 		$20K Hold
324
– – ﹤0.01% 382
2020
Q3 		$26K Hold
324
– – 0.01% 324
2020
Q2 		$20K Hold
324
– – 0.01% 303
2020
Q1 		$17K Buy
324
+20
+7% +$1.98K 0.01% 277
2019
Q4 		$37K Buy
304
+4
+1% +$575 0.01% 343
2019
Q3 		$54K Buy
300
+90
+43% +$12.7K 0.02% 320
2019
Q2 		$27K Buy
+210
New +$37.6K 0.01% 318

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moloney Securities Asset Management's TXMD Position: Q1 2021 in Review

Moloney Securities Asset Management sold out of TherapeuticsMD (TXMD) in Q1 2021, closing a stake of 324 shares — an estimated $20K sold.

Moloney Securities Asset Management first reported a position in TXMD in Q2 2019 and held it in 7 quarters. The position peaked at $54K in Q3 2019. 160 funds tracked by Wall St. Rank hold TXMD as of Q1 2021.

  • Moloney Securities Asset Management reported no remaining TherapeuticsMD position as of Q1 2021 after selling out during the quarter.
  • Moloney Securities Asset Management sold 324 TherapeuticsMD shares in Q1 2021, an estimated $20K.
  • Moloney Securities Asset Management first reported a position in TherapeuticsMD in Q2 2019 and held it in 7 quarters.
  • Moloney Securities Asset Management's TherapeuticsMD position peaked at $54K in Q3 2019.
  • 160 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2021.

Based on Moloney Securities Asset Management's 13F filing for Q1 2021, filed 28 Apr 2021.